Session » Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science
- 1:00PM-2:30PM
-
Abstract Number: 2565
A Randomized, Double-blind, Multicenter, Parallel-arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab-1000 and Prolia in Postmenopausal Women with Osteoporosis
- 1:00PM-2:30PM
-
Abstract Number: 2566
Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study
- 1:00PM-2:30PM
-
Abstract Number: 2563
Efficacy and Safety Results of CT-P41 (Proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial
- 1:00PM-2:30PM
-
Abstract Number: 2567
Gene Expression in Osteonecrosis of the Femoral Head: A Region-matched RNA-sequencing Study
- 1:00PM-2:30PM
-
Abstract Number: 2568
Incidence of First Fracture in RA Is Increasing Faster Than the General Population
- 1:00PM-2:30PM
-
Abstract Number: 2564
Providing Optimal and Equitable Osteoporosis Treatment Using a Programmatic Approach -A 20 Year Longitudinal Study